scholarly journals Effectiveness of social media in reducing risk factors for noncommunicable diseases: a systematic review and meta-analysis of randomized controlled trials

2016 ◽  
Vol 74 (4) ◽  
pp. 237-247 ◽  
Author(s):  
George Mita ◽  
Cliona Ni Mhurchu ◽  
Andrew Jull
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Social Media ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Noncommunicable Diseases ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Almond Consumption and Risk Factors for Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

2019 ◽  
Vol 10 (6) ◽  
pp. 1076-1088 ◽  
Author(s):  
Michelle A Lee-Bravatti ◽  
Jifan Wang ◽  
Esther E Avendano ◽  
Ligaya King ◽  
Elizabeth J Johnson ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Body Weight ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Meta Analyses

ABSTRACT Evidence suggests that eating nuts may reduce the risk of cardiovascular disease (CVD). We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating almond consumption and risk factors for CVD. MEDLINE, Cochrane Central, Commonwealth Agricultural Bureau, and previous systematic reviews were searched from 1990 through June 2017 for RCTs of ≥3 wk duration that evaluated almond compared with no almond consumption in adults who were either healthy or at risk for CVD. The most appropriate stratum was selected with an almond dose closer to 42.5 g, with a control most closely matched for macronutrient composition, energy intake, and similar intervention duration. The outcomes included risk factors for CVD. Random-effects model meta-analyses and subgroup meta-analyses were performed. Fifteen eligible trials analyzed a total of 534 subjects. Almond intervention significantly decreased total cholesterol (summary net change: −10.69 mg/dL; 95% CI: −16.75, −4.63 mg/dL), LDL cholesterol (summary net change: −5.83 mg/dL; 95% CI: −9.91, −1.75 mg/dL); body weight (summary net change: −1.39 kg; 95% CI: −2.49, −0.30 kg), HDL cholesterol (summary net change: −1.26 mg/dL; 95% CI: −2.47, −0.05 mg/dL), and apolipoprotein B (apoB) (summary net change: −6.67 mg/dL; 95% CI: −12.63, −0.72 mg/dL). Triglycerides, systolic blood pressure, apolipoprotein A1, high-sensitivity C-reactive protein, and lipoprotein (a) showed no difference between almond and control in the main and subgroup analyses. Fasting blood glucose, diastolic blood pressure, and body mass index significantly decreased with almond consumption of >42.5 g compared with ≤42.5 g. Almond consumption may reduce the risk of CVD by improving blood lipids and by decreasing body weight and apoB. Substantial heterogeneity in eligible studies regarding almond interventions and dosages precludes firmer conclusions.

Effects of strawberry supplementation on cardiovascular risk factors: a comprehensive systematic review and meta-analysis of randomized controlled trials

2019 ◽  
Vol 10 (11) ◽  
pp. 6987-6998 ◽  
Author(s):  
Amir Hadi ◽  
Moein Askarpour ◽  
Maryam Miraghajani ◽  
Michael E. Symonds ◽  
Ali Sheikhi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Cardiovascular Risk ◽  
Randomized Controlled Trials ◽  
Cardiovascular Risk Factors ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Freeze Dried

Based on our findings, strawberry supplements that contained 10–454 g day−1 freeze-dried/fresh strawberries and taken for 3–12 weeks can improve DBP, CRP, MDA and LDL.

Carnosine and histidine-containing dipeptides improve dyslipidemia: a systematic review and meta-analysis of randomized controlled trials

2020 ◽  
Vol 78 (11) ◽  
pp. 939-951
Author(s):  
Kirthi Menon ◽  
Clara Marquina ◽  
Pernille Hoj ◽  
Danny Liew ◽  
Aya Mousa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Cardiovascular Risk ◽  
Randomized Controlled Trials ◽  
Total Cholesterol ◽  
Burden Of Disease ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Controlled Trials ◽  
Randomized Controlled

Abstract Context Cardiovascular disease is a major public health problem and represents a significant burden of disease globally. Lifestyle interventions have their limitations and an intervention that will effectively address cardiovascular risk factors to help reduce this growing burden of disease is required. Objective Carnosine and other histidine-containing dipeptides (HCDs) have exerted positive effects on cardiovascular risk factors and diseases in animal and human studies. The authors conducted a systematic review and meta-analysis examining the effects of HCDs on cardiovascular outcomes in line with the PRISMA guidelines. Data Sources The Medline, Medline in process, Embase, Cumulative Index of Nursing and Allied Health, and All EBM databases were searched from inception until January 25, 2019, for randomized controlled trials (RCTs) examining the effects of HCDs on cardiovascular outcomes, compared with placebo or controls. Data Extraction Basic characteristics of the study and populations, interventions, and study results were extracted. The grading of recommendations assessment, development, and evaluation approach was used to assess the quality of evidence for each outcome. Data Analysis A total of 21 studies were included. Of these, 18 were pooled for meta-analysis (n = 913). In low risk of bias studies, HCD-supplemented groups had lower total cholesterol (n = 6 RCTs; n = 401; weighted mean difference [WMD], −0.32 mmol/L [95%CI, −0.57 to −0.07], P = 0.01) and triglyceride levels (n = 6 RCTs; n = 401; WMD, −0.14 mmol/L [95%CI, −0.20 to −0.08], P < 0.001) compared with controls. In studies using carnosine, triglycerides levels were also lower in the intervention group vs controls (n = 5 RCTS; n = 309; P < 0.001). There were no significant differences in blood pressure, heart rate, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C) or the total cholesterol to HDL-C ratio between groups. Conclusions Carnosine and other HCDs may have a role in improving lipid profiles. Larger studies with sufficient follow-up are necessary to confirm these findings and explore the use of HCDs in the prevention of cardiovascular diseases. Systemic Review Registration PROSPERO registration no.: CRD42017075354

Effect of mediterranean diets on cardiovascular risk factors and diseases in the primary prevention setting: a systematic review and meta-analysis of randomized controlled trials

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A.V Hernandez ◽  
A Piscoya ◽  
K.M Marti ◽  
K.E Marti ◽  
V Pasupuleti ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Primary Prevention ◽  
Randomized Controlled Trials ◽  
Clinical Outcomes ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Obese Patients ◽  
Randomized Controlled ◽  
Subgroup Analyses

Abstract Background The effects of Mediterranean diets (MED) on various health parameters suggest potential cardiovascular (CV) health benefits. Purpose We evaluated the effects of MED for primary prevention of CV risk factors and disease in overweight or obese adults. Methods A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed using PRISMA guidelines. PubMed, EMBASE, Web of Science, Scopus, Cochrane Library, clinicaltrials.gov, and clinicaltrialsregister.eu were searched until January 2020. RCTs evaluating any type of MED compared to other diets or advice in adults were included. Predefined CV risk factors were lipid, liver, glucose, anthropometric, and blood pressure outcomes. Clinical outcomes were all cause mortality, CV mortality, myocardial infarction (MI), coronary artery disease, stroke, cerebrovascular disease, and diabetes. Meta-analyses of random effects models were performed and effects were described as mean difference (MD) and their 95% confidence intervals (CI). Subgroup analyses by weight, type of MED, type of control, and trial duration were performed when heterogeneity was high (I2>60%). Results Eighteen RCTs (n=915) were included. Two RCTs evaluated only obese patients, 13 evaluated overweight and obese patients, and three did not specify. Fifteen RCTs evaluated MED alone while three evaluated MED combined with another diet. Thirteen RCTs evaluated effects of another diet while five evaluated diet advice or no treatment as controls. The median time to follow up was 6 months (range 6 weeks to 24 months). Clinical outcomes were only described in the revised 2018 PREDIMED trial where MED were associated with 35% lower risk of MI, stroke, and CV death vs advice (HR 0.65, 95% CI 0.50 to 0.85). MED were significantly associated with lower levels of triglycerides (TG) (MD −12.70 mg/dL, 95% CI −18.58 to −6.82), waist circumference (WC) (MD −1.92 cm, 95% CI −3.59 to −0.24), weight (MD −1.75 kg, 95% CI −2.82 to −0.69), and body mass index (BMI) (MD −0.69 kg/m2, 95% CI −1.11 to −0.27), and higher levels of HDL (MD 2.03 mg/dL, 95% CI 1.13 to 2.92) compared to other diets or advice. MED did not significantly change any other CV risk factors. Subgroup analyses showed some differences vs main analyses, but were based on a small set of RCTs in most of cases. Excluding five high risk of bias RCTs showed significant reductions in total cholesterol (MD −6.57 mg/dL, 95% CI −12.22 to −0.93), Fatty Liver Index (MD −23.30, 95% CI −30.20 to −16.40), HOMA-IR (MD −0.53, 95% CI −1.02 to −0.05), and SBP (MD −2.35 mmHg, 95% CI −4.02 to −0.68). Conclusion MED significantly decreased TG and anthropometric outcomes, and increased HDL when compared to other diets or advice. There was no significant association between MED and the other predefined CV risk factors. Newer RCTs without the flaws of PREDIMED are needed to further evaluate clinical outcomes. Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document